Colony-stimulating factors: a new step in clinical practice. Part II.
Clinical application of colony-stimulating factors (CSFs) such as recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human granulocyte macrophage colony-stimulating factor (rhGM-CSF) are advancing rapidly now that these factors are approved as indicated therapy in patients with chemotherapy-induced neutropenia, patients undergoing autologous bone marrow transplantation (BMT) and patients who develop graft failure after BMT. Novel CSFs are also being explored for potential clinical application in situations not as significantly affected by rhG-CSF or rhGM-CSF. Studies determining unique effects of novel factors, combinations of factors and combinations with peripheral blood progenitor cell fusions which may lead to future clinical applications of CSFs will be reviewed.
Nemunaitis
J
J
Hematopoiesis Program, Western Pennsylvania Cancer Institute, West Penn Hospital, Pittsburgh 15224.
D016026:Bone Marrow Transplantation; D002986:Clinical Trials as Topic; D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D006801:Humans; D011994:Recombinant Proteins
D003115:Colony-Stimulating Factors; D011994:Recombinant Proteins